2006
DOI: 10.2298/vsp0611975r
|View full text |Cite
|
Sign up to set email alerts
|

Extramedular plasmacytoma in the urinary bladder: Unusual localization

Abstract: When renal failure associated with hematuria and bilateral hydronephrosis is presented in a patient with multiple myeloma, this unusual and rare extramedular localization should be also considered.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
0
1
1

Year Published

2010
2010
2021
2021

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 8 publications
0
0
1
1
Order By: Relevance
“…The symptoms at presentation can be highly variable. Several reports have highlighted the need for accurate immunohistochemical analysis to distinguish between plasmacytoma and transitional cell carcinoma, particularly in patients without a prior history of myeloma [1,2,3]. However, unlike the case that we report here, all of the previous cases to date exhibited an exophytic tumour mass at diagnosis.…”
Section: Discussioncontrasting
confidence: 59%
“…The symptoms at presentation can be highly variable. Several reports have highlighted the need for accurate immunohistochemical analysis to distinguish between plasmacytoma and transitional cell carcinoma, particularly in patients without a prior history of myeloma [1,2,3]. However, unlike the case that we report here, all of the previous cases to date exhibited an exophytic tumour mass at diagnosis.…”
Section: Discussioncontrasting
confidence: 59%
“…Die intravesikale Myelommanifestation ist extrem selten; eine Medline-Recherche (06.11.2009, Stichwörter: "plasmocytoma, bladder, haematuria") ergab 18 bis dato beschriebene Fälle des blasenbefallenden Plasmozytoms [6,7,8,9,10] sowie 1 Fall mit ureteralem Befall [11]. Bei unserem Patienten fiel der urinzytologische Befund im Rahmen der präoperativen Diagnostik negativ [8,12] Um den Galenus-von-Pergamon-Preis können sich Arzneimittel bewerben, die zum Zeitpunkt der Einreichung bereits seit einem Jahr in Deutschland zugelassen und in den Verkehr gebracht worden sind.…”
Section: Introductionunclassified